Casdin Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Casdin Capital’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-75,000	Closed	-$5.85M	–	61
2021 Q2	$5.85M	Hold	75,000	–	–	0.15%	48
2021 Q1	$7.09M	Hold	75,000	–	–	0.21%	42
2020 Q4	$9.14M	Hold	75,000	–	–	0.27%	43
2020 Q3	$6.55M	Hold	75,000	–	–	0.29%	41
2020 Q2	$4.84M	Hold	75,000	–	–	0.29%	39
2020 Q1	$3.35M	Hold	75,000	–	–	0.36%	37
2019 Q4	$4.67M	Hold	75,000	–	–	0.43%	30
2019 Q3	$2.82M	Buy	75,000 +15,000	+25%	+$653K	0.29%	32
2019 Q2	$2.44M	Buy	+60,000	New	+$2.14M	0.23%	30

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Casdin Capital's TPTX Position: Q3 2021 in Review

Casdin Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021, closing a stake of 75,000 shares — an estimated $5.85M sold.

Casdin Capital first reported a position in TPTX in Q2 2019 and held it in 9 quarters. The position peaked at $9.14M in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

Casdin Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Casdin Capital sold 75,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $5.85M.
Casdin Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Casdin Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.14M in Q4 2020.
190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.